Company news

Enveric Biosciences, Inc. news in 2023

Enveric Biosciences, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

December 28, 2023

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

December 27, 2023

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

December 26, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives

November 28, 2023

Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)

November 23, 2023

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

November 12, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin

October 30, 2023

Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders

October 17, 2023

Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit

October 10, 2023

Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates

October 2, 2023

Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry

September 26, 2023

Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates

September 19, 2023

Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives

September 10, 2023

Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives

September 4, 2023

Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs

August 27, 2023

Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program

August 20, 2023

Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results

August 13, 2023

Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373

July 23, 2023

Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373

July 16, 2023

Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing

June 25, 2023

Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)

June 6, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates

June 4, 2023

Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023

May 29, 2023

Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug

May 23, 2023

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

May 17, 2023

Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

May 14, 2023

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

April 2, 2023

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

March 22, 2023

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

March 20, 2023

Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery

March 13, 2023

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 27, 2023

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 22, 2023

Decks in 2023